At K 2013 through October 23, SABIC is highlighting engineered thermoplastics and polymer technologies for healthcare product applications. Products include solutions for flexible packaging, for drug delivery, and for minimizing healthcare-associated infections.
Global contract development and manufacturing organization (CDMO) Aesica has acquired new manufacturing equipment capable of processing 5000 prefilled syringes per batch. Currently undergoing validation via process simulation trials, this latest addition to Aesica's Nottingham site will enable the CDMO to support clients across the EU and U.S. markets. Validation is expected to be completed by January 2014.
To help migraine sufferers select appropriate treatment at the onset of symptoms, Zogenix Inc. has redesigned and relaunched its SUMAVEL DosePro Migraine Toolbox provided through physicians. The updated kit contains a sample dose of the SUMAVEL DosePro Needle-free Delivery System (sumatriptan injection) along with educational aids, a journal for tracking migraine attacks and treatments, pharmacy support materials, and a compact carrying case. Zogenix’s goal is to educate patients about new U.S.
Member states of the European Union are now expected to pass national legislation aimed at preventing sharps injuries. EU Council Directive (2010/32/EU), which took effect May 11, 2013, aims “to achieve the safest possible working environment by preventing injuries to workers caused by all medical sharps (including needle-sticks),” reads the document. In other words, hospitals as well as other workplaces where healthcare services are provided are expected to take steps to protect employees from needle sticks.
Pharmapack North America exhibitor TOPAS Advanced Polymers has provided TOPAS cyclic olefin copolymer (COC) for a recently upgraded insulin pump. The next-generation OmniPod Insulin Management System upgraded by developer Insulet Corp. features an insert molded plunger made from TOPAS COC. The tubeless and wireless insulin pump offers people living with insulin-requiring diabetes a portable solution.
Pharmapack North America takes place this week (June 18-19) in Philadelphia.
Pharmapack North America will take place June 18-19 in Philadelphia. The exhibition will bring together exhibitors offering blister packaging, closures, bottles, cardboard packaging, labeling, printing technologies, components and subassemblies, contract manufacturing, traceability and anticounterfeit technologies, dispensing systems, drug-delivery devices and components, and injectable technologies and components. Read below for a preview of the exhibition and a few highlights from the conference.
The Lantus & You Journal for Lantus SoloSTAR is among the finalists in the 15th Annual Medical Design Excellence Awards (MDEA). Manufactured by Sanofi US, the Lantus & You Journal is designed for patients with Type 2 diabetes who are new to using the Lantus SoloSTAR insulin injection pen. The journal provides a step-by-step guide using a human-centered approach to self-care.
Today’s pharmaceuticals are increasingly being delivered via novel routes, and many are designed for patients to use when treating themselves. “Drug products are undergoing design revisions, giving changing patient populations user-friendly options,” explains Don Singer, Global Lead Quality Manager, Microbiology R&D, GlaxoSmithKline. “It is not just pills and tablets any more. We are seeing many inhalable and intranasal products, and parenterals are no longer just delivered directly by standard syringes and from vials, especially in the oncology field.
Secondary packaging is undergoing innovation. At Pharmapack Europe, Perfecseal exhibited a solution consisting of an inner tray and a clear plastic outer carton utilizing the company’s PerfecLink interlocking mechanism.
Alan Shortall, founder and CEO of Unilife Corp., senses a shift in healthcare. “About 50% of all healthcare will be administered outside of healthcare facilities and outside the home within ten years,” he says, quoting an E&Y report. “Healthcare will increasingly be self-injected by patients while they are on the go, such as at work or even the gym.”